Adebrelimab

Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal PD-L1 (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC) [1][2].

Product Specifications

CAS Number

[2247114-85-6]

Product Name Alternative

SHR-1316

UNSPSC

12352203

Target

Apoptosis; PD-1/PD-L1

Type

Inhibitory Antibodies

Related Pathways

Apoptosis; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/adebrelimab.html

Purity

97.84

Solubility

10 mM in DMSO

Smiles

[Adebrelimab]

Molecular Weight

(145.56 kDa)

References & Citations

[1]Zhiwei Liu, et al. The Synergistic Effects of Pyrotinib and SHR-1316 on HER2-positve breast cancer. Research Square. May 19th, 2022.|[2]Wanpu Yan, et al. Adebrelimab (SHR-1316) in combination with chemotherapy as perioperative treatment in patients with resectable stage II-III NSCLC: an open-label, multicenter, phase 1b trial. J Thorac Oncol. 2022 Sep 30; S1556-0864 (22) 01822-6.